Acumen Pharmaceuticals Q3 EPS $(0.35) Beats $(0.37) Estimate
Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 20.45 percent increase over losses of $(0.44) per share
Share
Why It Matters
Acumen lost less money than Wall Street expected this quarter. When a losing company loses less than people thought, that is good progress to notice.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.